Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Inflammatory Effects of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis

NCT01036022 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01036022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01036022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Inflammatory Effects of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
September 15, 2009
Completion date
January 10, 2013
Enrollment
120 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

colitis, ulcerative